Please Wait.....
Report
Non-Injectable Insulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Pills, Sprays, and Others), By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores), By Region and Competition, 2020-2030F
Market Report I 2025-05-16 I 186 Pages I TechSci Research
Market Overview
The Global Non-Injectable Insulin Market was valued at USD 3.14 Billion in 2024 and is projected to reach USD 5.45 Billion by 2030, growing at a CAGR of 9.63% during the forecast period. This market encompasses insulin formulations designed to be administered without needles, offering alternatives to traditional injection-based delivery. Non-injectable insulin options-such as oral pills, inhalable forms, sprays, and patches-are being developed to improve patient adherence and quality of life, especially for individuals who face challenges with injections. These delivery systems aim to offer a more user-friendly experience while maintaining effective blood glucose control. Despite the promise, the market faces hurdles due to clinical setbacks; for instance, Oramed Pharmaceuticals' oral insulin candidate ORMD-0801 failed to meet its primary endpoint, and Biocon halted a Phase 1 trial of Tregopil for Type 1 diabetes. However, with continued innovation and patient-centric product development, non-injectable insulin therapies are expected to gain traction as a viable alternative for diabetes management.
Key Market Drivers
Improved Glycemic Control
Enhanced glycemic control is a pivotal driver of growth in the Global Non-Injectable Insulin Market. Traditional injectable insulin can be uncomfortable, often leading to poor compliance. Non-injectable delivery systems address this by offering less invasive options, improving patient adherence and reducing anxiety associated with needle use. These alternatives also support earlier initiation of insulin therapy, allowing better management of blood glucose levels and delaying the progression of diabetes-related complications. By accommodating patients with physical limitations or needle aversion, these technologies increase treatment accessibility and improve health outcomes. The availability of user-friendly insulin forms also encourages adoption among previously reluctant patient populations, thereby expanding the market base and accelerating growth.
Key Market Challenges
Efficacy and Safety Concerns
Concerns over the effectiveness and safety of non-injectable insulin continue to hinder broader market adoption. While these alternatives promise improved convenience, they must demonstrate clinical efficacy equivalent to traditional injections to gain widespread acceptance. Issues such as variable absorption rates and inconsistent glucose control can create doubts among healthcare professionals. Furthermore, the potential for unknown long-term side effects associated with newer delivery technologies adds to skepticism. Regulatory bodies require robust evidence to approve such therapies, and without it, product launches may be delayed or restricted. This uncertainty affects physician confidence and limits patient uptake, ultimately restraining market expansion.
Key Market Trends
Personalized Treatment Approaches
The growing trend toward personalized medicine is significantly shaping the Global Non-Injectable Insulin Market. Tailoring treatment strategies to individual patient needs-considering factors like lifestyle, age, comorbidities, and psychological preferences-enhances therapy adherence and outcomes. Non-injectable insulin options provide flexibility that supports this personalization. For instance, oral formulations may better suit elderly patients with dexterity issues, while sprays may appeal to younger demographics seeking ease and discretion. Customized treatment protocols that incorporate these delivery systems can minimize patient discomfort and improve disease management. This trend aligns with the broader healthcare movement toward patient-centered care and is expected to contribute significantly to the market's long-term growth.
Key Market Players
- Midatech Pharma Plc
- Shreya Life Sciences Pvt. Ltd.
- Boston Therapeutics, Inc.
- Coromed, Inc.
- Diabetology Ltd.
- Emisphere Technologies, Inc.
- Oramed Pharmaceuticals, Inc.
- Diasome Pharmaceuticals, Inc.
- Generex Biotechnology Corp.
- Biodel, Inc.
Report Scope:
In this report, the Global Non-Injectable Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Non-Injectable Insulin Market, By Product:
o Pills
o Sprays
o Others
- Non-Injectable Insulin Market, By Distribution Channel:
o Hospital Pharmacies
o Online Pharmacies
o Drug Stores
- Non-Injectable Insulin Market, By Region:
o North America
United States
Canada
Mexico
o Europe
France
United Kingdom
Italy
Germany
Spain
o Asia-Pacific
China
India
Japan
Australia
South Korea
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Non-Injectable Insulin Market.
Available Customizations:
Global Non-Injectable Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Non-Injectable Insulin Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Pills, Sprays, and Others)
5.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.4. By Company (2024)
5.3. Market Map
5.3.1. By Product
5.3.2. By Distribution Channel
5.3.3. By Region
6. North America Non-Injectable Insulin Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-Injectable Insulin Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Distribution Channel
6.3.2. Canada Non-Injectable Insulin Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Distribution Channel
6.3.3. Mexico Non-Injectable Insulin Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Distribution Channel
7. Europe Non-Injectable Insulin Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Non-Injectable Insulin Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Distribution Channel
7.3.2. Germany Non-Injectable Insulin Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Distribution Channel
7.3.3. United Kingdom Non-Injectable Insulin Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Distribution Channel
7.3.4. Italy Non-Injectable Insulin Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Distribution Channel
7.3.5. Spain Non-Injectable Insulin Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Distribution Channel
8. Asia-Pacific Non-Injectable Insulin Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Non-Injectable Insulin Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Distribution Channel
8.3.2. India Non-Injectable Insulin Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Distribution Channel
8.3.3. Japan Non-Injectable Insulin Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Distribution Channel
8.3.4. South Korea Non-Injectable Insulin Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Distribution Channel
8.3.5. Australia Non-Injectable Insulin Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Distribution Channel
9. South America Non-Injectable Insulin Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Non-Injectable Insulin Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Distribution Channel
9.3.2. Argentina Non-Injectable Insulin Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Distribution Channel
9.3.3. Colombia Non-Injectable Insulin Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Distribution Channel
10. Middle East and Africa Non-Injectable Insulin Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Non-Injectable Insulin Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Distribution Channel
10.3.2. Saudi Arabia Non-Injectable Insulin Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Distribution Channel
10.3.3. UAE Non-Injectable Insulin Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Non-Injectable Insulin Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Midatech Pharma Plc
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.2. Product Offerings
15.1.3. Recent Developments
15.1.4. Financials (As Reported)
15.1.5. Key Personnel Details
15.1.6. SWOT Analysis
15.2. Shreya Life Sciences Pvt. Ltd.
15.3. Boston Therapeutics, Inc.
15.4. Coromed, Inc.
15.5. Diabetology Ltd.
15.6. Emisphere Technologies, Inc.
15.7. Oramed Pharmaceuticals, Inc.
15.8. Diasome Pharmaceuticals, Inc.
15.9. Generex Biotechnology Corp.
15.10. Biodel, Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security